ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO688

Voclosporin Induces Systemic Lipidomic Alterations: Implications in the Remission of Lupus Nephritis

Session Information

Category: Glomerular Diseases

  • 1303 Glomerular Diseases: Clinical‚ Outcomes‚ and Trials


  • Afshinnia, Farsad, University of Michigan, Ann Arbor, Michigan, United States
  • Rehaume, Linda M., Aurinia Pharmaceuticals Inc, Victoria, British Columbia, Canada
  • Cross, Jennifer, Aurinia Pharmaceuticals Inc, Victoria, British Columbia, Canada
  • Huizinga, Robert B., Aurinia Pharmaceuticals Inc, Victoria, British Columbia, Canada
  • Pennathur, Subramaniam, University of Michigan, Ann Arbor, Michigan, United States

Voclosporin is a novel calcineurin inhibitor indicated for the treatment of adults with active lupus nephritis (LN). Cardiovascular disease (CVD) is a major cause of morbidity and mortality in SLE patients, and LN is an independent CVD risk factor. The AURORA 1 trial showed favorable renal clinical response and changes in traditional lipoproteins with voclosporin. We hypothesize that the beneficial therapeutic response is mediated in part by alteration in circulating lipids.


In a lipidomic analysis, 918 serum lipids in 14 classes from baseline and week 52 of randomly selected participants from control (placebo) (N=30) and voclosporin (N=28) arms of the AURORA 1 trial (, NCT03021499; EudraCT, 2016–004045–81) were compared. All patients received MMF and low-dose steroids. The difference of lipids at week 52 from baseline was calculated, z-score standardized, and used in mixed linear models.


The alterations of lipid class levels were assessed as a function of voclosporin effect and by achievement of either complete renal response (CRR) or partial renal response (PRR) (Table). Voclosporin and renal clinical response (CRR or PRR) contributed to decline in CERs and TAGs and increase in DCERs and PIs independent of each other. Results indicate the additive effects of voclosporin and renal clinical response on alteration of corresponding lipids. Voclosporin, CRR and PRR were independently associated with alteration of PC(C16), PIs, and TAGs. An integrative analysis showed significant correlations between saturated DAGs and MAGs (C>16), TAGs, SMs, CERs, unsaturated PEPs, and palmitoyl PCs(C16) after controlling for CRR or PRR.


CERs, DCERs, PIs, and TAGs are altered by voclosporin. Alterations of PC, PI and TAGs correlate with renal outcome independent of voclosporin. Collectively, these findings suggest that voclosporin reduces lipogenesis by decreasing incorporation of fatty acid precursors, and a favorable therapeutic response is mediated in part by promotion of change in corresponding lipid class.


  • Commercial Support – Aurinia Pharmaceuticals Inc.